EGFR and neoplasm: Another promising strategy was developed by Choi and colleagues, who used the tumor-specific antigen EGFR-vIII to direct T cells selectively to the tumor through the CAR and these T cells secrete a bispecific antibody that binds both EGFR and CD3 to recruit T cells to EGFR+ tumor cells within the tumor [113].